United Therapeutics (UTHR) is back on investors’ radar after the U.S. FDA granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an external liver assist product aimed at patients with acute liver failure.

The RMAT designation arrives at a time when momentum in United Therapeutics’ shares has been strong, with a 12.23% 1 month share price return and a 25.70% 3 month share price return, contributing to a 1 year total shareholder return of 106.99%.

If breakthroughs in organ and liver support are on your radar, it may also be worth scanning for other health focused opportunities through Simply Wall St’s 37 healthcare AI stocks.

With the shares already posting strong recent returns and the stock trading at a discount to both some intrinsic value estimates and the average analyst price target, the key question is whether there is still a buying opportunity here or if the market is already pricing in future growth.

Most Popular Narrative: 8.6% Undervalued

The most followed narrative puts United Therapeutics' fair value at $644.08 per share, slightly above the last close of $588.38, framing recent gains within a still constructive valuation story.

The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine. This can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.

Curious what kind of revenue growth, margins, and future earnings multiple sit behind that fair value number? The narrative leans on detailed forecasts, product launches, and capital allocation moves that most investors only glimpse in the headlines.

Result: Fair Value of $644.08 (UNDERVALUED)

However, there is still real risk that future clinical readouts or regulatory decisions disappoint, or that competing PAH therapies and generics put pressure on United Therapeutics' core treprostinil franchise.

Next Steps

The mix of optimism and caution around United Therapeutics only matters if you weigh the details yourself, so take a moment to review the 3 key rewards.

Looking for more investment ideas?

Do not stop with a single company when tools can highlight fresh opportunities across different styles and risk levels in minutes, before others catch on.

• Target potential mispricings by scanning 60 high quality undervalued stocks that pair quality fundamentals with room for the market to reassess their worth.
• Prioritise resilience by filtering for 71 resilient stocks with low risk scores that may better align with a steadier risk profile.
• Hunt for under-the-radar potential using the screener containing 23 high quality undiscovered gems that many investors are not looking at yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.